Hostname: page-component-848d4c4894-nmvwc Total loading time: 0 Render date: 2024-06-25T23:32:57.118Z Has data issue: false hasContentIssue false
  • English
  • Français

Identification of Patients With Pseudomonas aeruginosa Respiratory Tract Infections at Greatest Risk of Infection With Carbapenem-Resistant Isolates

Published online by Cambridge University Press:  02 January 2015

Thomas P. Lodise Jr. ,
Chris Miller ,
Nimish Patel ,
Jeffrey Graves  and
Louise-Anne McNutt
Thomas P. Lodise Jr.*
Affiliation:
Pharmacy Practice Department, Albany College of Pharmacy, Albany, New York Ordway Research Institute, Albany, New York
Chris Miller
Affiliation:
Pharmacy Practice Department, Albany College of Pharmacy, Albany, New York Division of HIV Medicine, Albany Medical College, Albany, New York
Nimish Patel
Affiliation:
Pharmacy Practice Department, Albany College of Pharmacy, Albany, New York
Jeffrey Graves
Affiliation:
Pharmacy Practice Department, Albany College of Pharmacy, Albany, New York
Louise-Anne McNutt
Affiliation:
Department of Epidemiology, School of Public Health, University at Albany, State University of New York, Albany, New York
*
Pharmacy Practice, Albany College of Pharmacy, 106 New Scotland Ave., Albany, NY 12208-3492 (lodiset@acp.edu)
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective.

To create a clinical tool based on institution-specific risk factors to estimate the probability of carbapenem resistance among Pseudomonas aeruginosa isolates obtained from infected patients. By better estimating the probability of carbapenem resistance on the basis of patient-specific factors, clinicians can refine their empirical therapy for P. aeruginosa infections and potentially maximize clinical outcomes by increasing the likelihood of appropriate empirical antimicrobial therapy.

Design.

A retrospective, cross-sectional study.

Setting.

Tertiary care academic hospital.

Patients.

All adult inpatients who had a respiratory tract infection due to P. aeruginosa between January 2001 and June 2005.

Intervention.

Data on demographic characteristics, antibiotic history, and microbiology were collected. Log-binomial regression was employed to identify predictors of carbapenem resistance among P. aeruginosa isolates and to devise the clinical prediction tool.

Results.

Among 351 patients with P. aeruginosa infection, 44% were infected with carbapenem-resistant P. aeruginosa strains. Independent predictors of carbapenem resistance were prior receipt of mechanical ventilation for 11 days or more, prior exposure to fluoroquinolones for 3 days or more, and prior exposure to carbapenems for 3 days or more.

Conclusions.

With carbapenem resistance rates among P. aeruginosa isolates on the rise at our institution, the challenge was to identify patients for whom carbapenems would remain an effective empirical agent, as well as the patients at greatest risk for infection with carbapenem-resistant strains. The clinical prediction tool accurately estimated carbapenem resistance among this risk-stratified cross-sectional study of patients with P. aeruginosa infection. This tool may be an effective way for clinicians to refine their selection of empirical antibiotic therapy and to maximize clinical outcomes by increasing the likelihood of appropriate antibiotic treatment.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 28 , Issue 8 , August 2007 , pp. 959 - 965
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Kang, CI, Kim, SH, Kim, HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003;37:745–751.Google Scholar
2. Kang, CI, Kim, SH, Park, WB, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005;49:760–766.Google Scholar
3. Kollef, MH, Sherman, G, Ward, S, Fraser, VI. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462–474.CrossRefGoogle ScholarPubMed
4. Leibovici, L, Shraga, I, Drucker, M, Konigsberger, H, Samra, Z, Pitlik, SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998;244:379–386.Google Scholar
5. Lodise, TP, McKinnon, PS, Swiderski, L, Rybak, MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003;36:1418–1423.Google Scholar
6. Micek, ST, Lloyd, AE, Ritchie, DJ, Reichley, RM, Fraser, VJ, Kollef, MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49:1306–1311.CrossRefGoogle ScholarPubMed
7. Kollef, MH. Appropriate empiric antimicrobial therapy of nosocomial pneumonia: the role of the carbapenems. Respir Care 2004;49:1530–1541.Google ScholarPubMed
8. Livermore, DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002;34:634–640.Google Scholar
9. Tacconelli, E, Tumbarello, M, Bertagnolio, S, et al. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: analysis of trends in prevalence and epidemiology. Emerg Infect Dis 2002;8:220–221.Google Scholar
10. Obritsch, MD, Fish, DN, MacLaren, R, et al. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004;48:4606–4610.CrossRefGoogle ScholarPubMed
11. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470–485.Google Scholar
12. Garner, JS, Jarvis, WR, Emori, TG, Horan, TC, Hughes, JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128–140.Google Scholar
13. Knaus, WA, Draper, EA, Wagner, DP, Zimmerman, JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818–829.Google Scholar
14. Criteria Commitee, New York Heart Association. Diagnosis of the Heart and Blood Vessels: Nonmenclature and Criteria for Diagnosis. 7th ed. Boston: Little, Brown; 1973.Google Scholar
15. Clinical Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard-Ninth Edition. Wayne, PA: CLSI; 2006:M02–M9.Google Scholar
16. Zhang, H, Burthon, S. Recursive partitioning in the health sciences. In: Dietz, K, Gail, M, Krickeberg, K, Singer, B, eds. Recursive Partitioning in the Health Sciences. New York: Springer; 1999:226.Google Scholar
17. McNutt, LA, Wu, C, Xue, X, Hafner, JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 2003;157:940–943.CrossRefGoogle ScholarPubMed
18. Spiegelman, D, Hertzmark, E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol 2005;162:199–200.Google Scholar
19. Lodise, TP Jr, McKinnon, PS, Rybak, M. Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance. Infect Control Hosp Epidemiol 2003;24:655–661.Google Scholar
20. Harris, AD, Smith, D, Johnson, JA, Bradham, DD, Roghmann, MC. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002;34:340–345.Google Scholar
21. Zavascki, AP, Cruz, RP, Goldani, LZ. Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients. J Hosp Infect 2005;59:96–101.Google Scholar
22. Ozkurt, Z, Ertek, M, Eroi, S, Altoparlak, U, Akcay, MN. The risk factors for acquisition of imipenem-resistant Pseudomonas aeruginosa in the burn unit. Burns 2005;31:870–873.Google Scholar
23. Troillet, N, Samore, MH, Carmeli, Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997;25:1094–1098.Google Scholar
24. Lautenbach, E, Weiner, MG, Nachamkin, I, Bilker, WB, Sheridan, A, Fishman, NO. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006;27:893–900.Google Scholar
25. Piddock, LI. Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994. Drugs 1995;49(suppl 2):29–35.CrossRefGoogle ScholarPubMed
26. Suvarna, SK, al-Wali, WI, Locke, TJ. Morphological changes in Pseudomonas aeruginosa secondary to ciprofloxacin. Histopathology 1997;31:482–483.Google Scholar
27. Pai, H, Kim, J, Kim, I, Lee, JH, Choe, KW, Gotoh, N. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2001;45:480–484.CrossRefGoogle ScholarPubMed
28. Aubert, G, Pozzetto, B, Dorche, G. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy. J Antimicrob Chemother 1992;29:307–312.Google Scholar
29. Epp, SF, Kohler, T, Plesiat, P, Michea-Hamzehpour, M, Frey, J, Pechere, JC. C-terminal region of Pseudomonas aeruginosa outer membrane porin OprD modulates susceptibility to meropenem. Antimicrob Agents Chemother 2001;45:1780–1787.Google Scholar
30. Kohler, T, Epp, SF, Curty, LK, Pechere, JC. Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa . J Bacteriol 1999;181:6300–6305.Google Scholar
31. Kohler, T, Michea-Hamzehpour, M, Epp, SF, Pechere, JC. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother 1999;43:424–427.CrossRefGoogle ScholarPubMed
32. Harris, AD, Carmeli, Y, Samore, MH, Kaye, KS, Perencevich, E. Impact of severity of illness bias and control group misclassification bias in case-control studies of antimicrobial-resistant organisms. Infect Control Hosp Epidemiol 2005;26:342–345.Google Scholar
33. Harris, AD, Samore, MH, Lipsitch, M, Kaye, KS, Perencevich, E, Carmeli, Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, enterococci, and Escherichia coli . Clin Infect Dis 2002;34:1558–1563.CrossRefGoogle ScholarPubMed